Candriam S.C.A. Mirum Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 508,475 shares of MIRM stock, worth $21.4 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
508,475
Previous 508,475
-0.0%
Holding current value
$21.4 Million
Previous $17.4 Million
14.07%
% of portfolio
0.12%
Previous 0.11%
Shares
1 transactions
Others Institutions Holding MIRM
# of Institutions
190Shares Held
54MCall Options Held
177KPut Options Held
167K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$277 Million13.79% of portfolio
-
Janus Henderson Group PLC London, X04.48MShares$189 Million0.09% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.45MShares$145 Million2.37% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$137 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.08MShares$130 Million3.81% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.55B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...